Morgan Stanley Downgrades Pinterest to Equal-Weight, Lowers Price Target to $30

Morgan Stanley analyst Brian Nowak downgrades Pinterest (NYSE:PINS) from Overweight to Equal-Weight and lowers the price target from $53 to $30.

byBenzinga Newsdesk

March 29, 2022

1 minute read

Morgan Stanley analyst Brian Nowak downgrades Pinterest (NYSE:PINS) from Overweight to Equal-Weight and lowers the price target from $53 to $30.

General
News

Adient Partners With Venture Capital Company EnerTech

By Shivani Kumaresan

Today, 3:09 AM

Automotive seating provider Adient PLC (NYSE:ADNT) has entered into a strategic partnership with a venture capital firm, EnerTech Capital. EnerTech focuses on emerging…

ADNT

News

Sports Entertainment Acquisition Provides Update On Audit Committee Requirements And Business Combination Amendment

By Benzinga Newsdesk

Today, 3:09 AM

Sports Entertainment Acquisition Corp. (NYSE:SEAH) (the "Company") announced today that it received a notice from the New York Stock Exchange (the "NYSE") indicating that the Company was deficient in

SEAH

Biophytis Stock Gains As Sarconeos High Dose Improves Gait Speed Versus Placebo In Patients With Muscle Loss Due To Aging

By Vandana Singh

Today, 3:09 AM

Biophytis SA (NASDAQ:BPTS) has announced top-line results of the SARA-INT phase 2 clinical study with Sarconeos (BIO101) in sarcopenia patients. Sarcopenia…

BPTS

Textron Q4 EPS $1.07 Beats $1.00 Estimate, Sales $3.64B Beat $3.32B Estimate

By Bill Haddad

Today, 3:09 AM

Textron (NYSE:TXT) reported quarterly earnings of $1.07 per share which beat the analyst consensus estimate of $1.00 by 7 percent. This is a 13.83 percent increase over earnings of $0.94 per share from the same period

TXT

Morgan Stanley Downgrades Pinterest to Equal-Weight, Lowers Price Target to $30

Related Posts

Adient Partners With Venture Capital Company EnerTech

Sports Entertainment Acquisition Provides Update On Audit Committee Requirements And Business Combination Amendment

Biophytis Stock Gains As Sarconeos High Dose Improves Gait Speed Versus Placebo In Patients With Muscle Loss Due To Aging

Textron Q4 EPS $1.07 Beats $1.00 Estimate, Sales $3.64B Beat $3.32B Estimate